1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
KOREA UNITED PHARM, INC.

KOREA UNITED PHARM, INC.

KKRX:033270
17,200.00
KRW
-230.00
(-1.32%)
4,985.14EPS
3.50P/E
276.77BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
8,516.79
9,826.16
10,323.33
11,576.84
13,307.58
14,313.07
14,939.73
14,557.16
14,890.95
17,731.43
19,061.8
19,651.6
19,704.27
19,510.84
Basic EPS, GAAP
759.8
1,163.44
1,384
1,277
1,882
2,139
2,087
1,794
1,930
3,058
3,298
2,209
2,614
4,985.14
Free Cash Flow per Basic Share
412.57
743.73
527.95
1,094.71
6.13
1,318.07
1,241.78
1,645.9
2,108.35
2,672.99
1,261.51
379.27
1,773.6
2,556.27
Dividend per Share
115.61
48.07
202.66
221.8
250.01
299.97
329.83
329.9
349.98
370.94
402.03
418.03
451.73
- -
Book Value per Share
9,131.23
10,174.19
11,164.07
11,980.96
13,621.84
15,431.99
17,201.26
18,654.34
20,258.97
22,970.86
25,897.56
27,611.96
31,480.46
31,342.43
Tangible Book Value per Share
8,979.55
9,949.62
10,878.4
11,611.1
13,183.07
15,057.23
16,797.59
18,235.08
19,769.31
22,372
25,258.58
26,985
30,749.69
30,656.74
Basic Weighted Avg Shares
16
16
16
15
15
15
15
15
15
15
15
15
15
15
Sales/Revenue/Turnover
136,891
155,190
162,046
176,905
197,023
211,936
221,311
215,950
221,040
262,522
278,943
288,707
288,765
298,081
Operating Margin (%)
10.84
14.17
14.14
15.33
16.1
17.81
15.81
18.58
15.03
18.37
19.82
11.61
17.35
16.82
Depreciation Expense
6,175
7,152
6,616
7,373
7,436
7,337
7,270
8,496
7,673
8,989
10,094
11,270
11,558
11,262
Net Income, GAAP
12,212
18,375
21,725
19,514
27,864
31,672
30,916
26,613
28,649
45,275
48,262
32,453
38,308
76,162
Effective Tax Rate (%)
21.61
18.88
12.56
28.93
2.29
20.7
19.77
25.35
27.44
15.25
19.68
29.59
23.11
15.04
Profit Margin (%)
8.92
11.84
13.41
11.03
14.14
14.94
13.97
12.32
12.96
17.25
17.3
11.24
13.27
25.55
Working Capital
66,166
83,002
73,458
75,748
77,656
92,382
105,817
121,133
143,503
158,512
172,140
196,558
220,927
245,724
LT Debt
18,307
19,779
13,392
10,572
7,000
6,650
11,885
11,386
12,971
8,232
11,832
13,824
11,896
11,558
Total Equity
141,437
161,835
171,991
177,387
201,682
228,482
255,099
276,891
300,709
337,856
378,681
406,207
454,629
497,115
Return on Invested Capital (%)
7.16
10.01
10.24
9.54
14.32
12.14
9.97
9.86
7.33
11.42
11.04
9.28
8.47
8.87
Return on Capital (%)
8.07
10.85
11.56
10.02
13.3
13.29
11.56
9.01
8.98
13.1
12.59
7.8
8.63
16.22
Return on Common Equity (%)
8.89
12.12
13.02
11.17
14.7
14.73
12.79
10.01
9.92
14.18
13.47
8.27
8.9
16.72

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,129
2,567
3,301
LT Borrowings
10,804
9,882
10,711
LT Finance Leases
1,092
866
847
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
16
16
Market Capitalization
275,402
314,836
276,771

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
268,678
291,717
300,072
Cash, Cash Equivalents & STI
157,066
171,651
178,556
Accounts Receivable, Net
38,504
45,394
45,551
Inventories
64,257
64,898
66,513
Total Current Liabilities
47,751
86,864
54,347
Payables & Accruals
- -
- -
- -
ST Debt
2,129
2,567
3,301
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.25%
10.44%
11.92%
Free Cash Flow
2,171.93%
59.59%
366.48%
Net Income, GAAP
8.75%
11.51%
18.04%
Sales/Revenue/Turnover
6.1%
6.18%
0.02%
Total Cash Common Dividend
7.71%
6.23%
7.79%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
73,173
70,994
71,356
73,183
288,707
2025
71,348
70,374
74,393
72,649
288,765
2026
73,817
77,221
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,312
-434
357
978.83
2,209
2025
860
81
923.43
747.59
2,614
2026
875.98
2,377
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
418.03
2025
- -
- -
- -
- -
451.73
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Duk-Young Kang
Full Time Employees
902
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Nonhyeon-ro 121street 22 Sejong-si SE South Korea 339-841
IPO Date
Oct 23, 2007
Website
kup.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Korea United Pharm Inc. (033270.KS) manufactures and markets a broad portfolio of pharmaceutical products with a focus on incrementally modified drugs (IMDs), prescription (ETC) and over-the-counter (OTC) medications; core offerings span respiratory system remedies such as Levotics CR tablets (levodropropizine); musculo-skeletal anti-inflammatories including Clanza CR tablets (aceclofenac); gastro-intestinal treatments like Gastin CR tablets (mosapride); cardiovascular and antithrombotic agents encompassing Cilostan CR tablets (cilostazol), Clavixin Duo capsules (clopidogrel plus aspirin), and the recently approved Siloduo (cilostazol plus rosuvastatin); anti-infectives such as Augmex Duo tablets; anti-cancer injectables and tablets numbering approximately 30 kinds including Adricin (doxorubicin HCl), Tezomin (bortezomib), Unitrexate (methotrexate), Glotib (imatinib mesylate), Erlotib (erlotinib HCl), Cycram (cyclophosphamide), and Hydrine capsules (hydroxyurea); central nervous system therapies; vitamins, nutritional agents, hormones, analgesics, anti-osteoporosis drugs, anti-ulcerants, iron chelators, and corticosteroids; as well as new launches like Pitaric capsules for dyslipidemia and Sereterol Actvair inhaler for chronic obstructive pulmonary disease (COPD). The company, founded in 1987 and headquartered in Sejong, South Korea, with prior operations noted in Seoul, primarily serves domestic doctors and hospitals while exporting to over 40 countries across Southeast Asia, Latin America including Colombia, Venezuela, Brazil, and Panama via free trade zones, Africa such as Angola, Europe, the US, Canada, Japan, Saudi Arabia, and the Philippines where it maintains branch offices; it operates export-oriented factories including an oncology-specialized facility in Sejong certified under PIC/S GMP since 2015. Recent developments include construction of a new Sejong plant to double annual production capacity from KRW 300 billion to KRW 600 billion supporting expanded IMD supply and pipeline growth; regulatory approvals and launches of Siloduo, Pitaric, and Sereterol Actvair in 2025 targeting KRW 145 billion-plus domestic markets to drive sales beyond KRW 300 billion for the first time; and advancement of four new drugs via joint venture U&S Bio with Seoul National University Holdings, notably a semaglutide biosimilar slated for Korean launch by 2028 alongside immuno-oncology, diabetes, and obesity therapies.